319 related articles for article (PubMed ID: 28545466)
41. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
42. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
[TBL] [Abstract][Full Text] [Related]
43. Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy.
Nicaise EH; Schmeusser BN; Ali A; Midenberg E; Palacios AR; Hartsoe B; Kearns E; Ambadi S; Patil DH; Joshi SS; Narayan VM; Psutka SP; Nazha B; Brown JT; Ogan K; Bilen MA; Master VA
Clin Genitourin Cancer; 2024 Jun; 22(3):102056. PubMed ID: 38443295
[TBL] [Abstract][Full Text] [Related]
44. The Relationship Between Red Cell Distribution Width and Cancer-Specific Survival in Patients With Renal Cell Carcinoma Treated With Partial and Radical Nephrectomy.
Życzkowski M; Rajwa P; Gabrys E; Jakubowska K; Jantos E; Paradysz A
Clin Genitourin Cancer; 2018 Jun; 16(3):e677-e683. PubMed ID: 29339043
[TBL] [Abstract][Full Text] [Related]
45. Clinical implications of preoperative serum total cholesterol in patients with clear cell renal cell carcinoma.
Ohno Y; Nakashima J; Nakagami Y; Gondo T; Ohori M; Hatano T; Tachibana M
Urology; 2014 Jan; 83(1):154-8. PubMed ID: 24149106
[TBL] [Abstract][Full Text] [Related]
46. Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma.
Obata J; Tanaka N; Mizuno R; Kanao K; Mikami S; Matsumoto K; Kosaka T; Kikuchi E; Jinzaki M; Oya M
BJU Int; 2016 Oct; 118(4):598-603. PubMed ID: 26780664
[TBL] [Abstract][Full Text] [Related]
47. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.
Capitanio U; Zini L; Perrotte P; Shariat SF; Jeldres C; Arjane P; Pharand D; Widmer H; Péloquin F; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2008 Nov; 72(5):1090-5. PubMed ID: 18799207
[TBL] [Abstract][Full Text] [Related]
48. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
Culp SH; Tannir NM; Abel EJ; Margulis V; Tamboli P; Matin SF; Wood CG
Cancer; 2010 Jul; 116(14):3378-88. PubMed ID: 20564061
[TBL] [Abstract][Full Text] [Related]
49. The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma.
Yuk HD; Kang M; Hwang EC; Park JY; Jeong CW; Song C; Seo SI; Byun SS; Kwak C; Hong SH; Chung J; Lee H;
Investig Clin Urol; 2020 Sep; 61(5):475-481. PubMed ID: 32734724
[TBL] [Abstract][Full Text] [Related]
50. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
51. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
52. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.
Janisch F; Klotzbücher T; Marks P; Kienapfel C; Meyer CP; Yu H; Fühner C; Hillemacher T; Mori K; Mostafei H; Shariat SF; Fisch M; Dahlem R; Rink M
World J Urol; 2021 Aug; 39(8):2977-2985. PubMed ID: 33649869
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
54. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
[TBL] [Abstract][Full Text] [Related]
55. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.
Lenis AT; Burton CS; Golla V; Pooli A; Faiena I; Johnson DC; Salmasi A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K
Urol Oncol; 2019 Sep; 37(9):577.e9-577.e16. PubMed ID: 30930099
[TBL] [Abstract][Full Text] [Related]
56. The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma.
Kang HW; Kim SM; Kim WT; Yun SJ; Lee SC; Kim WJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kim HH; Kwak C; Byun SS; Kim YJ;
J Cancer Res Clin Oncol; 2020 Jan; 146(1):187-196. PubMed ID: 31606760
[TBL] [Abstract][Full Text] [Related]
57. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
58. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
[TBL] [Abstract][Full Text] [Related]
59. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
[TBL] [Abstract][Full Text] [Related]
60. Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.
Belsante M; Darwish O; Youssef R; Bagrodia A; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
Urol Oncol; 2014 Jan; 32(1):30.e23-8. PubMed ID: 23428539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
